25 jul: Europa/aktier: Nervøsitet gemt, men ikke glemt
25 jul: Valuta: 5 dages fald i euro vendt til stigning
25-07-2012 14:05:00

Bristol-Myers Profit Falls 28%

Relateret indhold

Bristol-Myers Squibb Co.'s (BMY) second-quarter profit declined 28%, as sales were eroded by recent patent expirations for top-selling drugs including the anticlotting pill Plavix.

The New York drug maker also lowered its forecast of full-year 2012 earnings.

Bristol-Myers plans to get through the patent losses for Plavix and other drugs by boosting sales of newer drugs. The company hopes to bolster its product lineup with its recent agreement to purchase diabetes-drug maker Amylin Pharmaceuticals Inc. (AMLN) for $5.3 billion.

In May, Bristol-Myers lost U.S. patent protection for Plavix, which is used to stave off recurrent heart attacks and strokes. This exposed the brand to lower-priced competition from generic versions, and Bristol's second-quarter Plavix sales tumbled 60% to $741 million. Bristol-Myers co-markets the drug with Sanofi (SNY).

Another blow was the March loss of patent protection for blood-pressure medications Avapro and Avalide, which pushed combined sales of those drugs down 53% to $117 million.

Bristol and other drug makers are in the midst of a wave of patent expirations for blockbuster drugs that have pressured sales. Bristol has had some success bringing new drugs to market to help offset the patent losses, but it also has experienced some research setbacks.

For the second quarter, Bristol's profit fell to $645 million, or 38 cents a share, from $902 million, or 52 cents a share, a year earlier. Excluding certain costs such as asset impairments, earnings were 48 cents a share, matching the mean estimate of analysts surveyed by Thomson Reuters.

Overall sales declined 18% to $4.44 billion, just ahead of the Thomson mean estimate.

U.S. sales dropped 27% to $2.6 billion, while non-U.S. sales fell 1% to $1.9 billion.

Although sales for Plavix and the blood-pressure medications declined substantially, sales for other top products increased, ranging from a 1% gain for antipsychotic Abilify to a 71% jump for skin-cancer treatment Yervoy.

Bristol-Myers continues to try to bring more drugs to market. One of the most closely watched is Eliquis, an anticlotting drug co-developed with Pfizer Inc. (PFE). The U.S. Food and Drug Administration declined to approve it in June, asking for more information about clinical data. Analysts believe the drug could be a multibillion-dollar seller.

Bristol also is developing new drugs for cancer and hepatitis C that have shown promise in studies.

The company, however, recently disclosed negative clinical results for experimental liver-cancer drug brivanib. And the FDA has declined to approve the diabetes drug dapagliflozin, developed in partnership with AstraZeneca PLC (AZN).

Bristol said Wednesday an advisory committee of the European Union issued a positive opinion on the company's proposed subcutaneous formulation of anti-inflammatory drug Orencia. A European Commission decision is pending.

The company lowered its forecast of 2012 earnings to a range of $1.78 to $1.88 a share from a prior range of $1.90 to $2 a share. However, Bristol didn't change its forecast of adjusted earnings, which exclude certain items, of $1.90 to $2 a share. Bristol said the unchanged adjusted earnings forecast factors in the expected three-cents-a-share negative impact related to the planned Amylin acquisition.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 25, 2012 08:05 ET (12:05 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

G4S mister en kontrakt efter øvsag

04-09-2015 16:32:13
G4S har genvundet én af to kontrakter på at drive træningscentre for unge kriminelle i Storbritannien.Efter en skandalesag om forholdene på Rainsbrook-centret, ..

Mærsk/Nykredit: Fragtrater får pil nedad

04-09-2015 14:21:20
Maersk Line fik i denne uge medvind af en stigning i fragtraterne på den store rute mellem Asien og Nordeuropa, og det er nu anden uge i træk, at raten stiger m..

Vestas henter tysk ordre på 39,6 megawatt

04-09-2015 11:28:47
Vestas fortsætter stimen af ordrer. Fredag kan den danske vindmølleproducent fortælle, at det har modtaget en bestilling i Tyskland på 39,6 megawatt til det bor..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
USA: Beskæftigelsesrapport overrasker markant negativt - NY
2
NNIT får amerikansk storaktionær
3
USA/økonomer: Økonomien kører fornuftigt trods uro i Kina
4
Fredagens aktier: ISS fejede negativt C20 af banen
5
Mærsk/Nykredit: Fragtrater får pil nedad

Relaterede aktiekurser

Pfizer Inc 31,37 -1,6% Fald i aktiekurs
Bristol-Myers Squibb Co 57,30 -2,5% Fald i aktiekurs
Astrazeneca PLC ORD SHS .. 4.181,50 -1,6% Fald i aktiekurs
Sanofi 87,17 -2,6% Fald i aktiekurs
Astrazeneca PLC 31,70 -1,7% Fald i aktiekurs
Sanofi 48,45 -2,3% Fald i aktiekurs
AstraZeneca PLC 538,50 -1,3% Fald i aktiekurs
Pfizer Inc 268,00 -1,5% Fald i aktiekurs
Pfizer Incorporated COM .. 31,46 -0,5% Fald i aktiekurs
Pfizer 31,00 -1,7% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
5. september 2015 16:16:59
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150903.1 - EUROWEB1 - 2015-09-05 16:16:59 - 2015-09-05 16:16:59 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x